Abstract
Currently, there is no evidence whether ganciclovir, or its oral prodrug valganciclovir, penetrates into the cerebrospinal fluid of human infants treated for congenital cytomegalovirus infection. Here, we report a case study providing evidence that ganciclovir, administered as valganciclovir, reaches the infant's cerebrospinal fluid when used at the currently recommended dose for congenital cytomegalovirus infection.
MeSH terms
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use*
-
Cytomegalovirus Infections / cerebrospinal fluid*
-
Cytomegalovirus Infections / congenital*
-
DNA, Viral / analysis
-
Female
-
Ganciclovir / administration & dosage
-
Ganciclovir / analogs & derivatives*
-
Ganciclovir / pharmacology
-
Ganciclovir / therapeutic use
-
Humans
-
Infant, Newborn
-
Pregnancy
-
Pregnancy Complications, Infectious
-
Valganciclovir
Substances
-
Antiviral Agents
-
DNA, Viral
-
Valganciclovir
-
Ganciclovir